Trimetazidine exerts protection against increasing current electroshock seizure test in mice

Trimetazidine, a novel anti-ischemic agent, is used in the therapy of angina, vertigo and chorioretinal diseases. It has also been examined for its effect on nociception, inflammation and neuroprotection in various animal models. The present study was designed to investigate the effect of trimetazidine on electrically induced seizures in mice. Trimetazidine was administered orally in doses of 5,10 and 20 mg/kg (single dose) to observe its effect on the increasing current electroshock seizure (ICES) test in mice. Trimetazidine in 10 and 20 mg/kg doses significantly raised the seizure-threshold current in the ICES test. Further, co-administration of per se ineffective dose of trimetazidine (5 mg/kg, p.o.) with sub-anticonvulsant dose of nimodipine (10 mg/kg, p.o.) and phenytoin (12.5 mg/kg, p.o.) offered significant protection in the ICES test. These results indicate that trimetazidine possesses significant anticonvulsant activity against electro-convulsions in the mice. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.